LOGIN  |  REGISTER
Assertio
Cue Biopharma

Varex Imaging to Hold Virtual Annual Meeting of Stockholders and Sets Annual Meeting and Record Dates

December 06, 2024 | Last Trade: US$8.37 0.11 1.33

SALT LAKE CITY / Dec 06, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced that its 2025 Annual Meeting of Stockholders will be held in virtual format only at 4:30 pm Mountain Time on Thursday, February 13, 2025. Stockholders will not be able to attend the 2025 annual meeting in person.

Varex stockholders of record at the close of business on December 16, 2024 will be entitled to receive notice of the Annual Meeting and to vote upon matters considered at the meeting.

Varex will make available to all stockholders of record important information about the Annual Meeting and the matters to be considered. Information on how to attend the virtual meeting will be included in the meeting materials to be sent to stockholders. Varex urges stockholders to vote and submit their proxies in advance of the meeting by one of the methods described in the proxy materials.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page